VIRGINIA COMMONWEALTH UNIVERSITY

INmune Bio's XPro™ (XPro1595, pegipanermin) significantly reduced amyloid formation and improved brain function in transgenic mice following traumatic brain injury.

Researchers report successful treatment of ciltacabtagene autoleucel-induced parkinsonism in multiple myeloma patients using the JAK inhibitor ruxolitinib, offering a potential solution for this serious complication.

A landmark Phase 3 clinical trial led by VCU and King's College London researchers found semaglutide significantly reduces liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Aramchol, Galmed Pharmaceuticals' SCD1 inhibitor, significantly enhanced the anti-tumor effects of Bayer's Regorafenib in liver and colorectal cancer models through increased autophagy and death receptor signaling.

A Phase 2 clinical trial of survodutide, a dual GLP-1 and glucagon agonist, demonstrated that up to 83% of patients with fatty liver disease showed measurable improvement after 48 weeks of treatment.